Lexaria Bioscience Corp. (NASDAQ: LEXX) has been pushing the boundaries of drug delivery through its patented DehydraTECH(TM) technology, which has evidenced more efficient delivery of active pharmaceutical ingredients (“APIs”) into the bloodstream while also increasing their bioavailability. “Its technology has seen application in pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter capsules, pills, tablets, and oral suspensions. Lexaria has explored its usage in the delivery of cannabinoids, nicotine, antivirals, PDE5 inhibitors, and more,” a recent article reads. “All of Lexaria’s efforts serve to demonstrate the superior performance of both its research program and its DehydraTECH drug delivery technology. By doing so, it is looking to tap into various markets, including but not limited to oral cannabinoids, oral mucosal nicotine, antivirals, human hormones, dementia, rheumatoid disease, and diabetes. Lexaria’s management hopes that, before the end of the 2022 calendar year, it will have built sufficient data to effect meaningful industry progress and sustainable increases in valuation to steer the conversation forward and allow for the greater adoption of DehydraTECH.”
To view the full article, visit https://cnw.fm/ZbMED
About Lexaria Bioscience Corp.
Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]
CannabisNewsWire is part of the InvestorBrandNetwork.